Retrospective longitudinal data (2013–2024) from six immunotherapy-naive MuSK-MG patients yielded 103 observations linking MuSK antibody levels to MG-ADL using generalized linear mixed-effects ...

Johnson & Johnson (NYSE:JNJ) has reported new data from its Phase 3 Vivacity-MG3 trial showing that its therapy IMAAVY ...

Decisions about thymectomy in myasthenia gravis (MG) depend on several variables. Two important categories are whether the patient's thymus gland has thymoma or not and what type of autoantibodies, if ...

A growing number of new treatments for myasthenia gravis (MG) are changing how doctors manage the disease and offering new options for people whose symptoms aren’t fully controlled. In recent years, ...

Edrophonium achieved 83.5% sensitivity and 87.7% specificity across 182 myasthenia gravis cases and 324 controls. Test positivity remained similar across postsynaptic acetylcholine receptor ...

Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ ...

Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ ...